Prediction of serum HIV-1 neutralization titers of VRC01 in HIV-uninfected Antibody Mediated Prevention (AMP) trial participants

VRC01 is being evaluated in the AMP efficacy trials, the first assessment of a passively administered broadly neutralizing monoclonal antibody (bnAb) for HIV-1 prevention. A key analysis will assess serum VRC01-mediated neutralization as a potential correlate of protection. To prepare for this analy...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Yunda, Zhang, Lily, Eaton, Amanda, Mkhize, Nonhlanhla N., Carpp, Lindsay N., Rudnicki, Erika, DeCamp, Allan, Juraska, Michal, Randhawa, April, McDermott, Adrian, Ledgerwood, Julie, Andrew, Philip, Karuna, Shelly, Edupuganti, Srilatha, Mgodi, Nyaradzo, Cohen, Myron, Corey, Lawrence, Mascola, John, Gilbert, Peter B., Morris, Lynn, Montefiori, David C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Novel Vaccines – Short Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8928800/
https://www.ncbi.nlm.nih.gov/pubmed/34213402
http://dx.doi.org/10.1080/21645515.2021.1908030

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8928800/
https://www.ncbi.nlm.nih.gov/pubmed/34213402
http://dx.doi.org/10.1080/21645515.2021.1908030

Ejemplares similares